Print Page    Close Window    

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
C
$1.18
 Stock is Up 0.02 (1.72%)
Bellerophon (Nasdaq: BLPH)
Data as of 09/21/18 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
08/29/18
Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference
WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel. Bellerophon Presentation Details Date:  Wednesday, September 5 Time:  9:10am Eastern Tim... 
08/07/18
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 75 enrolled subjects completing 16-weeks of treatment in the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH). The DMC has recommended that the tria... 
08/01/18
Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results
WARREN, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the second quarter ended June 30, 2018. “We are pleased to see continued progress in our clinical trials and look forward to several important catalysts for our INOpulse® programs in the second half of 2018,” said Fabian Tenenbaum, Chief Executive Officer o... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

© Bellerophon Therapeutics. All rights reserved.